Paradigm lowers target on Oncolytics, but says stock is still a buy


The results from Oncolytics’ (TSX:ONC) U.S. Phase Two pancreatic cancer study were “mixed” says Paradigm Capital analyst Alan Ridgeway, but the company’s lead product REOLYSIN still has a multi-billion dollar market opportunity and several near term catalysts. Yesterday, Oncolytics released patient data from its U.S. randomized Phase Two Pancreatic Cancer Study. The market response was […]

Oncolytics Slides After Pancreatic Study Results


Yesterday, after market close, Oncolytics (TSX:ONC, Nasdaq:ONCY) delivered underwhelming data from a Phase II cancer study, causing its stock to swoon today. The U.S. National Cancer Institute sponsored study evaluated Oncolytics experimental therapy, REOLYSIN, in combination with paclitaxel versus a control arm that included carboplatin and paclitaxel in patients with recurrent or metastatic pancreatic cancer. […]

Shares of Merus Labs rise after acquiring Sintrom from Novartis AG


Shares of Merus Labs (TSX:MSL) are up this morning on heavier than normal volume after the company announced that one of its wholly owned subsidiaries had acquired, in certain European countries, the right to manufacture, market and sell Sintrom, an anticoagulant indicated for the treatment and prevention of thromboembolic diseases. Sintrom has been available for […]

Immunovaccine CEO Marc Mansour talks to Cantech Letter

marc mansour2

The news from Liberia, Sierra Leone, Guinea, Nigeria and now Senegal is not good. The World Health Organization now believes the worst outbreak of Ebola ever, which has already killed more than 1500, could eventually infect as many as 20,000 people. The crisis has sent governments worldwide scrambling for potential treatments. Earlier this month, B.C.-based […]

BioSyent Keeps Momentum Going with Solid Q2 Earnings


BioSyent (TSXV:RX) today announced Q2 results that are indicative of the revenue and earnings momentum investors have to come to expect from this emerging specialty pharma company based in Ontario. As I have written previously in Cantech, I believe BioSyent is carving a path that is very similar to another Canadian specialty pharma success story […]

Antibe Therapeutics could shake up the NSAID market, says M Partners

While popular in both generic and prescription forms, NSAID such as Pfizer's arthritis treatment Celebrex have been known to cause small intestinal damage and bleeding.

Tiny Antibe Therapeutics (TSXV:ATE) may be set to shake up the massive NSAID market, says M Partners analyst Daniel Pearlstein. In a research report to clients yesterday, Pearlstein initiated coverage of Antibe Therapeutics with a “Buy” rating and a one-year target of $1.30, implying a 160% return at the time of publication. Pearlstein notes that […]

Prometic Life Sciences offers compelling risk/reward scenario, says Paradigm


ProMetic Life Sciences (TSX:PLI) offers a truly compelling risk/reward scenario, says Paradigm Capital analyst Alan Ridgeway. Last Thursday, ProMetic reported its Q2, 2014 results. The company posted revenue of $4.4-million, but delivered a net profit of $23.4-million due to the recognition of a gain on revaluation of the equity investment of its equity interest in […]

IMRIS is still undervalued, says Paradigm

At the Health Sciences Centre in Winnipeg last September, IMRIS introduced the the first VISIUS® Surgical Theatre in Canada that features both intraoperative MRI (iMRI) and angiography capability together in one three-room suite.

An overdue capital refresh cycle at hospitals is a likely catalyst for medical imaging leader IMRIS (TSX:IM), says Paradigm Capital analyst Alan Ridgeway. On Friday, IMRIS reported its second quarter, 2014 results. The company lost (US) $7.02-million on revenue of $4.3-million. The topline was down 58% from the $10.2-million the company delivered in the same […]

Halifax Biomedical To Participate in Horizon Health Network Lower Back Study


Horizon Health Network, the largest healthcare organization in Atlantic Canada, has announced the undertaking of a research study involving spine instability measurement technology developed by Halifax Biomedical Inc. (HBI). “At present, in some patients, there is a gap between patient symptoms and true abnormalities which can be identified with routine testing techniques including x-ray and […]

Tekmira’s TKM-Ebola treatment cleared by the FDA for use in worst outbreak ever


After being halted today at the market close, Tekmira (TSX:TKM) announced that the FDA had verbally confirmed it had modified the full clinical hold placed on its TKM-Ebola treatment, in light of the worst outbreak of the disease ever. Shares of the company are up more than 8% on the Nasdaq after-market. “We are pleased […]